Shalby Ltd. · NSE:SHALBY
Shalby — Q1 FY2025 Earnings Presentation
38 slides from Shalby's earnings presentation, Jul 8, 2024
Slide 1: Submission letter to stock exchanges
Shalby/SE/2024‐25/38 July 08, 2024 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.com Su
Slide 2: Investor Presentation Q1 FY2025
Investor Presentation Q1 FY2025
Slide 3: Agenda
AGENDA 01 SHALBY GROUP QUARTERLY AND ANNUAL PERFORMANCE PERFORMANCE 02 HOSPITAL BUSINESS QUARTERLY AND ANNUAL PERFORMANCE PERFORMANCE 03 HOMECARE BUSINESS QUARTERLY PERFORMANCE 04 FRANCHISE BUSINESS QUARTERLY PERFORMANCE 05 SHALBY ACADEMY QUARTERLY PERFORMANCE 06 IMPLANT BUSINESS QUARTERLY PERFORMAN
Slide 4: Financials Snapshot Q1 FY25
Financials Snapshot Q1 FY25 Consolidated Revenue at ₹ 2,886 mn in Q1 FY25 vs ₹ 2,400 mn in Q1 FY24 grew by 20.2 % YoY Consolidated EBITDA at ₹ 549 mn in Q1 FY25 vs ₹ 477 mn in Q1 FY24 grew by 15.1 % YoY Consolidated PBT at ₹ 304 mn in Q1 FY25 vs ₹ 330 mn in Q1 FY24 Consolidated Financial Highlights
Slide 5: Consolidated Performance Highlights – Q1 FY25
Consolidated Performance Highlights – Q1 FY25 Revenue (INR MN) EBITDA1 & Margin (INR MN) 549 2886 477 2400 19.87% 19.02% Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Up 20.2% Up 15.1% PBT & Margin (INR MN) PAT & Margin (INR MN) 330 208 304 147 8.7% 5.1% 13.7% 10.5% Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 4 1. EBITDA inc
Slide 6: Consolidated P/L & B/S – Q1 FY25
Consolidated P/L & B/S – Q1 FY25 Profit & Loss (INR Mn) Balance Sheet (INR Mn) Q1 Q1 Y-o-Y Gross 3,654 Particulars (Rs. Millions) Borrowings FY25 FY24 Growth Cash & Cash 1,974 Revenue 2,886 2,400 20.2% Equivalents EBITDA 549 477 15.1% Net Cash/(Debt) (1,680) EBITDA Margin % 19.02% 19.87% PBT 304 330
Slide 7: Diversification in Revenue Mix
High Growth Business Verticals Healthcare Conglomerate Building An Integrated Orthopedic Solutions Ecosystem Multi-Specialty Franchise Implant 11 Hospitals across western, northern 5 Hospital network USA based Knee & Hip and central India Manufacturing facility Synergistic Sustainable Business Model
Slide 8: A Legend and Visionary Doctorpreneur behind Shalby
A Legend and Visionary Doctorpreneur behind Shalby Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated “Zero Technique” that revolutionized Joint Replacement Surgery. A visionary entrepreneur, he transformed Shalby from a 6 bedded hospital in 199
Slide 9: Standalone Performance (Hospital Business)
STANDALONE PERFORMANCE (Hospital Business) 8
Slide 10: Hospital Business Highlights Q1 FY25
Hospital Business Highlights Q1 FY25 Global leader in Joint replacements with more than 1,50,000 surgeries Surgery Count and YoY Growth Operational Performance Q1 Q1 YoY Particulars FY25 FY24 Growth Arthroplasty Nephro & Urology In-Patient1 (Nos.) 22.792 20,661 10.31% 4240+ 3.1% 760+ 13.1% Out Patie
Slide 11: Standalone Business Highlights – Q1 FY25
Standalone Business Highlights – Q1 FY25 Financial Performance Revenue (INR Mn) EBITDA & Margin (INR Mn) 2402 581 2163 497 22.99% 24.15% Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Up 11.06% Up 16.6% PBT & Margin (INR Mn) PAT & Margin (INR Mn) 458 305 400 262 18.49% 19.68% 12.11% 12.68% Q1 FY24 Q1 FY25 Q1 FY24
Slide 12: Standalone P&L and B/S – Q1 FY25
Standalone P&L and B/S – Q1 FY25 Profit & Loss (INR Mn) Total Revenue to EBITDA 120.0% Q1 Q1 Particulars (Rs Mn) FY25 FY24 YoY Growth EBITDA 100.0% 23.0% 24.1% Materials and Total Revenue 2,402 2,163 11.06% 80.0% Consumables 26.4% 25.8% Fees to Doctors and 60.0% EBITDA 581 497 16.6% Consultants Empl
Slide 13: Hospital Business Highlights: Specialty Revenue Mix
Hospital Business Highlights Specialty Revenue Mix Q1 FY2024 Q1 FY20251 Others, Nephrology, 11% Others, Arthroplasty, 5% 13% 45% Nephrology, Neurology, 5% Arthroplasty, 4% 40% Neurology, Orthopaedic, 5% 8% Orthopaedic, 9% Oncology, 11% Critical Care Oncology, Critical Care & & General 10% General Ca
Slide 14: Hospital Business Highlights: Payor Mix
Hospital Business Highlights Payor Mix Q1 FY2024 Q1 FY20251 Government, 25% Self Pay, Government Self Pay, 33% 24% 35% Insurance, Insurance, 41% 42% Notes: 13 1. .Q1’FY25 numbers includes PK Healthcare performance.
Slide 15: Standalone Business CAGR Growth
Standalone Business CAGR Growth Shalby Continued to deliver high double-digit growth over the last 2 decades Revenue (INR Mn) EBITDA (INR Mn) 8504 1982 6598 1426 3284 778 1685 439 194 22 FY 2007 FY 2012 FY 2017 FY 2022 FY 2024 FY 2007 FY 2012 FY 2017 FY 2022 FY 2024 14
Slide 16: Shalby Sanar Q1'FY25 Highlights
Shalby Sanar Q1’FY25 Highlights Total IP Count Employees 22500+ ARPOB 1080+ Sanar 350+ Patients Total ₹79,154 International Expertise Served in Revenue 56% in Liver, Doctors & Centres :- Consultant FY23-24 of ₹23.77 OP Count revenue Total Bed Kidney, Ethiopia 50+ Cr. in ALOS 4.25 3650+ generated Cap
Slide 17: Homecare Business Highlights Q1 FY 2025
Homecare Business Highlights Q1 FY 2025 Q1 FY2025 Highlights Patients Served (Nos) Patients Served 7,302 in Q1 FY25 v/s 7,695 patients in Q1 FY24, down by 5.11% YoY 7,695 7302 Revenue booked Rs.38 mn during Q1 FY25 v/s Rs.36.5 mn during Q1 FY24, grew by 3.2% YoY Physio, Diagnostics and Pharmacy are
Slide 18: Clinical Update And Research Across Units during Q1 FY25
Clinical Update And Research Across Units during Q1 FY25 ▪ Microwave Ablation under L/A for Multinodular Goiter :- A Case of male 40Y old, presented with c/o of pain and redness in throat, left lobe thyroid nodule. Pt was examined and evaluated, after informed consent, microwave ablation was done un
Slide 19: Key Focus Areas For Future In Hospital business
Key Focus Areas For Future In Hospital business Global Leader in Joint Replacement with diversification in other specialties • Continue to maintain global leadership in joint replacements • Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care, General Medicine and Tra
Slide 20: Franchise Business
SHALBY ORTHOPEDICS CENTRE OF EXCELLENCE** FRANCHISE BUSINESS Build Health & Wealth » 19
Slide 21: Leveraging Expertise Through Franchise Asset Light Model
Leveraging Expertise Through Franchise Asset Light Model Franchise model will leverage Shalby expertise and enable to penetrate faster across pan-India Business models SOCE Performance in Q1 FY25 Franchise Owned – Shalby Operated (FOSO) 1. The franchise is responsible for setting up the centre and S
Slide 22: Shalby Academy
O SHALBY ACADEMY 21
Slide 23: Shalby Academy
Shalby Academy Q1 FY25 highlights Students Enrolled (In Nos) 1. More than 428 new students registered in Q1 FY24-25 in various disciplines like Physiotherapy, Nursing, Lab Technician Nutrition & 2,062 and dietetics, Clinical, Paramedics, Hospital Management, and Pharmacy as part of their academic ou
Slide 24: Implant Business
IMPLANT BUSINESS de "
Slide 25: Diversified into Knee and Hip Implant Manufacturing In California, USA
Diversified into Knee and Hip Implant Manufacturing In California, USA Backward integration in Orthopedics with Inhouse capacity to consume in India 80,000+ Vertically integrated In- Components High Quality US FDA house manufacturing Manufacturing Approved Implants Facility capacity Surgeon’s Traini
Slide 26: Implant Business Performance Q1 FY25
Implant Business Performance Q1 FY25 Total Constructs EBITDA Revenue Sold Rs. 259 mn Rs. (6.57) mn 3,475+ Geographical Sales Mix USA Customer Sales Mix Product Sales Mix Hip, 32% US 44% Retail,45% Q1 FY25 Q1 FY25 Q1 FY25 India 56% Knee,68% Wholesale, 55% 25
Slide 27: SAT Pillars and Strategy for FY2024-25
SAT 4 PILLARS FOR FY2024-25 SAT STRATEGY FOR FY2024-25 • New products Looking for another launch from 8 Mn$ through the Significantly lower Multi-vendor COGS across scratch. right products supply system • Improvement portfolio by across SEA with higher in the current (Malaysia), LATAM improving effi
Slide 28: Implant Business Roadmap
Implant Business Roadmap Shalby Advanced Technologies plans to become a Global player in a phased manner Existing Phase 1 Phase 2 Phase 3 Market Latin America Middle East Countries East Africa North America • Argentina • UAE • Kenya • Columbia • Saudi Arabia • Ethiopia Japan South-East and North • O
Slide 29: About Shalby
ABOUT SHALBY 28
Slide 30: Shalby At A Glance
Shalby At A Glance OPD clinics Presence 16 60 23 Orthopedic Implant Hospitals1 Domestic International2 Manufacturing in USA 30 Strength 2,350+ 4,600+ 1,150+ Years of Legacy Bed Capacity Total Employees3 Doctors4 Team Clinical Excellence #1 30+ ~3.3 million+ 150,000+ Global Ranking in Specialties Pat
Slide 31: 30 Years of ELITE Legacy
30 Years of ELITE Legacy Integrity Highest standards of transparency accountability, and corporate governance Learning Team-Work Laser sharp focus on A patient-centric focused upgrading the skills of team with a great blend of our team and building experience, diversity, fresh people capability thin
Slide 32: Our Journey & Expansion Plan
Our Journey & Expansion Plan • Sanar, Gurugram • Jaipur Shalby, Jaipur (237 beds) • Naroda Shalby, Ahmedabad (267 beds) 130 beds Vijay Shalby, Ahmedabad • Vapi Shalby, Vapi (146 beds) • Acquired 100% • • Surat Shalby, Surat (243 beds) • Lucknow SOCE, 40 beds 27 beds • Krishna Shalby, Ahmedabad (220
Slide 33: Hospitals Portfolio
Hospitals Portfolio Multispecialty Units (Owned and Operate) SG Shalby Vapi Shalby Indore Shalby Jaipur Shalby Krishna Shalby Mohali Shalby Naroda Shalby Jabalpur Shalby Surat Shalby Sanar Shalby 32
Slide 34: Franchise Hospital Portfolio
Franchise Hospital Portfolio Shalby Orthopedics Centre of Excellence (SOCE) Multispecialty Vijay Shalby Lucknow Shalby Zynova Shalby (Mumbai) (Shalby Operated) (Shalby Operated) (Shalby Managed) Udaipur Shalby Gwalior Shalby Ranchi Shalby (Shalby Managed) (Shalby Managed) (Shalby Managed) 33
Slide 35: Biggest Healthcare Corporate Group in Western and Central India
Biggest Healthcare Corporate Group in Western and Central India Domestic Presence…... PUNJAB ▪ Mohali – 145 beds Uttar Pradesh ▪ Lucknow – 40 beds DELHI ▪ Gurugram – 130 beds RAJASTHAN ▪ Jaipur – 237 beds Jharkhand GUJARAT Ranchi – 60 beds ▪ Ahmedabad o SG – 201 beds o Krishna – 220 beds o Naroda –
Slide 36: Sustainability Initiatives and Healthcare Awareness Programs
Sustainability Initiatives ESG Mindset “We at Shalby are embracing sustainability to drive new values to our business” Community Connect 65+ Healthcare Camps Trainings Healthcare Awareness Programs Workplace Wellness 6500+ Life impacted 4,000+ and 2,300+ Man Hours Clinical and Non-Clinical training
Slide 37: Experienced Board Of Directors
Experienced Board Of Directors Dr. Ashok Bhatia Mr. Tej Malhotra Ms. Sujana Shah Independent Independent Independent Director Director Director Dr. Ashok Bhatia, a senior pharma professional has Mr. Malhotra boasts four decades of international and Mrs. Sujana Shah, a practicing Chartered Accountant
Slide 38: Disclaimer and Contact Details
DISCLAIMER and CONTACT DETAILS No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as